Versant Ventures
Versant Ventures caters to the healthcare sector with early and later stage venture, private equity, and debt financing investments.
Business Model:
Revenue: $6M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Versant Ventures Information
Geographic Data
Address: One Sansome Street
City: San Francisco
State: CA
Zip: 94104
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
3,552,464Website Global Rank
3,632Website Monthly Traffic
Twitter Followers
Description
Versant Ventures is a healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and offices in Canada, the U.S., and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs.
Contact Phone:
+14158018100
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2016 | Rox Medical | Series E | 40M |
| 6/2015 | Inari Medical | Series B | 12.4M |
| 3/2009 | Rennovia | Series A | 16.3M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 1/2019 | Halio | Series D | 100M |
| 6/2002 | Salmedix | Series B | 27.5M |
| 6/2012 | Benvenue Medical | Series D | 25M |
| 6/2014 | Benvenue Medical | Series E | 40M |
| 2/2005 | Five Prime Therapeutics | Series C | 45M |
| 1/2009 | Acclarent | Venture Round | 26M |
| 8/2019 | Chinook Therapeutics | Series A | 65M |
| 9/2010 | OpGen | Series B | 0 |
| 12/2003 | Confirma | Venture Round | 3M |
| 6/2012 | Twelve | Series B | 15M |
| 5/2020 | Ventus Therapeutics | Series A | 60M |
| 1/2008 | Nexis Vision | Series A | 6M |
| 1/2006 | ForSight Labs | Venture Round | 2.4M |
| 9/2005 | Standard BioTools | Series D | 0 |
| 3/2006 | Helicos BioSciences | Series B | 40M |
| 9/2012 | Nuvaira | Series B | 10.6M |
| 4/2007 | ForSight Labs | Series A | 5M |
| 4/2008 | SpaceOAR | Series A | 0 |
| 12/2004 | CymaBay Therapeutics | Series B | 44M |
| 12/2012 | Minerva Surgical | Venture Round | 20M |
| 1/2004 | Amphora Discovery | Series B | 12.9M |
| 1/2018 | Metavention | Series C | 0 |
| 3/2004 | Jazz Pharmaceuticals | Series B | 0 |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 3/2013 | Achaogen | Series D | 18.9M |
| 5/2015 | NeuWave Medical | Series C | 25.3M |
| 8/2002 | Concuity | Series C | 16.3M |
| 11/2006 | Amira Pharmaceuticals | Series A | 4M |
| 8/2010 | Respicardia | Series C | 0 |
| 6/2004 | Ablation Frontiers | Series A | 3.6M |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 3/2009 | Inogen | Series E | 3M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 10/2018 | Gotham Therapeutics | Series A | 54M |
| 2/2006 | Ablation Frontiers | Series B | 15.1M |
| 6/2013 | ForSight Labs | Series B | 9.3M |
| 4/2005 | ParAllele Bioscience | Convertible Note | 6M |
| 7/2008 | Hicuity Health | Series B | 5M |
| 3/2009 | NovaLign Orthopaedics | Series B | 10M |
| 5/2016 | Nouscom | Series A | 13.6M |
| 1/2022 | Nested Therapeutics | Seed Round | 35M |
| 5/2012 | NeoVista | Venture Round | 6M |
| 1/2001 | Cameron Health | Series A | - |
| 1/2006 | Ambrx | Series B | 5M |
| 7/2006 | GluMetrics | Series B | 9M |
| 11/2017 | Nouscom | Series B | 48.8M |
| 12/2012 | Flexion Therapeutics | Series B | 20M |
| 5/2014 | Ceterix Orthopaedics | Series B | 18M |
| 8/2022 | Vector BioPharma | Series A | 0 |
| 7/2019 | Century Therapeutics | Series A | 250M |
| 1/2014 | Intuity Medical | Venture Round | 5.5M |
| 10/2008 | Lutonix | Series B | 20M |
| 9/2003 | NovaCardia | Venture Round | 22M |
| 3/2012 | Sequent Medical | Series C | 26M |
| 10/2013 | Inceptus | Series A | 4.7M |
| 5/2004 | NeoVista | Series A | 2M |
| 12/2005 | Acclarent | Series B | 25M |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 11/2012 | CardiAQ Valve Technologies | Series B | 37.3M |
| 7/2005 | Nanoplex Technologies | Series B | 2.5M |
| 11/2016 | Intuity Medical | Venture Round | 0 |
| 2/2013 | Nuvaira | Series C | 10M |
| 1/2018 | Intuity Medical | Venture Round | 0 |
| 12/2008 | Hotspur Technologies | Series A | 1.3M |
| 10/2013 | Inari Medical | Series A | 4.7M |
| 9/2021 | 858 Therapeutics | Series A | 0 |
| 7/2006 | ROX Medical | Series B | 10.1M |
| 6/2008 | ROX Medical | Series C | 33M |
| 9/2015 | Veran Medical Technologies | Venture Round | 0 |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 6/2018 | Akero Therapeutics | Series A | 65M |
| 3/2005 | Ambrx | Series A | 23.4M |
| 3/2014 | PIQUR Therapeutics | Series A | 32M |
| 1/2001 | Salmedix | Series A | - |
| 11/2006 | Intersection Medical Inc | Series B | 5M |
| 8/2011 | Intuity Medical | Series D | 12M |
| 9/2014 | Ivantis | Series B | 25M |
| 2/2021 | Vividion Therapeutics | Series C | 135M |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 11/2009 | CymaBay Therapeutics | Series E | 0 |
| 1/2009 | Synosia Therapeutics | Series B | 0 |
| 1/2009 | AlterG | Series B | 8M |
| 11/2015 | Crinetics Pharmaceuticals | Series A | 40M |
| 1/2010 | The Foundry | Series A | 3M |
| 4/2012 | Five Prime Therapeutics | Private Equity Round | 10M |
| 1/2016 | Benvenue Medical | Equity | 23M |
| 10/2009 | Flexion Therapeutics | Series A | 33M |
| 10/2011 | Realeve | Series C | 32M |
| 6/2013 | Veracyte | Series C | 28M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 2/2019 | Nuvaira | Equity | 79M |
| 8/2001 | Insulet | Series B | 11M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 11/2002 | Skylight Healthcare Systems | Series B | 7.8M |
| 1/2018 | Pandion Therapeutics | Series A | 58M |
| 11/2003 | NeoGuide Systems | Series B | 0 |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 12/2017 | Respicardia | Venture Round | 0 |
| 1/2017 | Halio | Series C | 65M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 9/2021 | iECURE | Series A | 50M |
| 4/2014 | AAVLife | Series A | 12M |
| 1/2017 | Therachon | Series A | 5M |
| 8/2020 | T-knife | Series A | 78.4M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 8/2018 | Therachon | Series B | 60M |
| 7/2013 | Audentes Therapeutics | Series A | 30M |
| 6/2015 | Sebacia | Series C | 12M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 4/2014 | Sequent Medical | Series D | 20M |
| 8/2006 | ImpediMed | Venture Round | 3.4M |
| 4/2011 | Halscion, Inc. | Venture Round | 3.5M |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 7/2006 | Ambrx | Series C | 52M |
| 7/2004 | LipoSonix | Series C | 27M |
| 4/2007 | NovaCardia | Series B | 18M |
| 10/2013 | Immune Design | Series C | 49M |
| 8/2008 | Glaukos | Series D | 35M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 9/2019 | Passage Bio | Series B | 110M |
| 6/2009 | Nexis Vision | Series B | 12M |
| 8/2021 | Jnana Therapeutics | Series B | 50M |
| 10/2004 | Concuity | Venture Round | 8.3M |
| 11/2017 | Oyster Point Pharmaceuticals | Series A | 22M |
| 12/2000 | Skylight Healthcare Systems | Series A | - |
| 1/2018 | Aligos Therapeutics | Series A | 100M |
| 6/2002 | Spiration | Series D | 22M |
| 9/2015 | Therachon | Series A | 35M |
| 11/2006 | Neurotech | Series B | 0 |
| 1/2020 | VectivBio | Series A | 35M |
| 12/2022 | Launchpad Therapeutics | Series A | 0 |
| 7/2015 | PIQUR Therapeutics | Series A | 19M |
| 10/2020 | RayzeBio | Series A | 45M |
| 7/2020 | Bright Peak Therapeutics | Series A | 35M |
| 10/2015 | Turnstone Biologics | Series A | 11.3M |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 9/2009 | Helicos BioSciences | Post-IPO Equity | 10M |
| 1/2008 | Inogen | Series E | 12.7M |
| 9/2012 | Rox Medical | Series D | 6M |
| 8/2012 | AlterG | Series C | 10M |
| 11/2006 | Impedance Cardiology Systems | Series B | 5M |
| 10/2009 | SpaceOAR | Series B | 6.1M |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 10/2010 | Synosia Therapeutics | Series C | 0 |
| 1/2007 | Synosia Therapeutics | Venture Round | 32.5M |
| 11/2022 | Jnana Therapeutics | Series C | 0 |
| 2/2007 | Trius Therapeutics | Series A | 20M |
| 12/2014 | Audentes Therapeutics | Series B | 42.5M |
| 4/2014 | RedBrick Health | Venture Round | 7.5M |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 3/2021 | Century Therapeutics | Series C | 0 |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 1/2017 | Ebb Therapeutics | Series B | 0 |
| 6/2017 | Repare Therapeutics | Series A | 68M |
| 2/2007 | Inogen | Series D | 22M |
| 2/2008 | PhaseRx | Series A | 20.2M |
| 2/2006 | Amphora Discovery | Series E | 4.4M |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 2/2017 | Vividion Therapeutics | Series A | 50M |
| 11/2021 | ViaLase | Series A | 27.3M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 3/2018 | Inari Medical | Series C | 20.9M |
| 3/2008 | Spiration | Series G | 18.5M |
| 2/2019 | Oyster Point Pharmaceuticals | Series B | 0 |
| 2/2007 | Vantage Oncology | Series D | 0 |
| 12/2001 | Pharmion | Venture Round | 65M |
| 11/2022 | iECURE | Series A | 0 |
| 5/2014 | Anokion | Series A | 37.5M |
| 2/2012 | Helicos BioSciences | Series A | 27M |
| 8/2021 | T-knife | Series B | 110M |
| 11/2019 | CODA Biotherapeutics | Series A | 15M |
| 9/2010 | Okairos | Series B | 20.5M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 9/2008 | ForteBio | Series C | 25M |
| 6/2009 | Ocular Therapeutix | Series C | 15M |
| 11/2003 | Saegis Pharmaceuticals | Series B | 30M |
| 12/2017 | Jnana Therapeutics | Series A | 50M |
| 5/2003 | Accelerator Corp. | Venture Round | 0 |
| 3/2009 | NeoVista | Series D | 18M |
| 7/2008 | Immune Design | Series A | 18M |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 10/2002 | Insulet | Series C | 22M |
| 8/2005 | Amira Pharmaceuticals | Series A | 3M |
| 11/2006 | NewHope Bariatrics | Private Equity Round | 18.5M |
| 10/2002 | Pharmion | Venture Round | 40M |
| 2/2018 | Quentis | Series A | 48M |
| 12/2019 | Pipeline Therapeutics | Series B | 0 |
| 4/2006 | MedManage Systems | Series D | 10.8M |
| 4/2021 | Capsida | Series A | 50M |
| 9/2014 | Zyga Technology | Series D | 2M |
| 3/2002 | Phenomix | Series A | 12M |
| 3/2004 | Insulet | Series D | 35.5M |
| 9/2014 | AcuFocus | Venture Round | 0 |
| 11/2018 | Aprea | Series C | 0 |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 10/2003 | Biospect | Series B | 27M |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 6/2004 | Inogen | Series B | 6M |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 2/2009 | WaveTec Vision | Series C | 20.1M |
| 5/2012 | Zyga Technology | Series C | 25M |
| 8/2006 | Vantage Oncology | Series C | 0 |
| 5/2011 | WaveTec Vision | Series D | 15.9M |
| 9/2007 | OpGen | Venture Round | 0 |
| 7/2017 | Sebacia | Series D | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 5/2005 | Vantage Oncology | Series C | 0 |
| 5/2020 | Monte Rosa Therapeutics | Series A | 32.5M |
| 4/2007 | Acclarent | Series C | 35M |
| 6/2021 | Stablix | Series A | 63M |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 6/2004 | Vantage Oncology | Series B | 0 |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 1/2004 | Spiration | Series E | 0 |
| 4/2015 | CRISPR Therapeutics | Series B | 29M |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 9/2008 | Microfabrica | Series B | 22.5M |
| 10/2006 | Achaogen | Series B | 26M |
| 4/2010 | Groove Biopharma | Series A | 3.9M |
| 7/2010 | Immune Design | Series B | 32M |
| 1/2008 | Confirma | Series C | 0 |
| 10/2005 | ForteBio | Series B | 17.3M |
| 7/2017 | Venatorx Pharmaceuticals | Series B | 42M |
| 9/2001 | Amphora Discovery | Series A | 35M |
| 2/2006 | Insulet Corporation | Series E | 0 |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 1/2010 | Intuity Medical | Series D | 64M |
| 5/2007 | WaveTec Vision | Series B | 13M |
| 1/2004 | Intuity Medical | Series B | 0 |
| 6/2021 | LENZ Therapeutics | Series A | 47M |
| 6/2020 | Lycia Therapeutics | Series A | 50M |
| 12/2020 | Gritstone Bio | Post-IPO Equity | 125M |
| 4/2006 | Spiration | Series F | 13.4M |
| 1/2004 | Novacea | Series C | 35M |
| 9/2020 | Graphite Bio | Series A | 45M |
| 11/2002 | Novacea | Series B | 36M |
| 2/2011 | NeoVista | Series E | 33M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 10/2008 | Respicardia | Series B | 0 |
| 1/2011 | Ocular Therapeutix | Series C | 6M |
| 8/2008 | GluMetrics | Series C | 20.1M |
| 11/2011 | AcuFocus | Private Equity Round | 0 |
| 6/2008 | Cameron Health | Series E | 0 |
| 4/2015 | Twelve | Series C | 35M |
| 4/2008 | Bird Rock Bio | Series A | 8M |
| 4/2013 | RedBrick Health | Private Equity Round | 14M |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 6/2013 | Ocular Therapeutix | Series D | 23.8M |
| 12/2015 | Kyras Therapeutics | Series A | - |
| 2/2011 | Glaukos | Series E | 0 |
| 9/2006 | NeoVista | Series B | 26M |
| 10/2021 | Tentarix Biotherapeutics | Series A | 50M |
| 8/2012 | ForSight VISION5 | Venture Round | 8M |
| 4/2011 | Benvenue Medical | Series C | 35.5M |
| 3/2009 | LensX Lasers | Series B | 22.4M |
| 4/2014 | ForSight VISION5 | Equity | 15M |
| 4/2014 | ForSight Labs | Series C | 15M |
| 4/2015 | CRISPR Therapeutics | Series A | 35M |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 11/2001 | ParAllele Bioscience | Series A | - |
| 3/2018 | Tempest Therapeutics | Series B | 70M |
| 2/2017 | Tarveda Therapeutics | Series D | 30M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 4/2013 | GenSight Biologics | Series A | 41.7M |
| 11/2016 | Turnstone Biologics | Series B | 0 |
| 7/2021 | Turnstone Biologics | Series D | 0 |
| 5/2018 | Lava Therapeutics | Series A | 18.7M |
| 9/2020 | Lava Therapeutics | Series C | 83M |
| 8/2011 | RedBrick Health | Series D | 5M |
| 6/2010 | Veracyte | Series B | 28M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 4/2009 | RedBrick Health | Series C | 15M |
| 5/2009 | Realeve | Series B | 20M |
| 6/2021 | RayzeBio | Series C | 108M |
| 1/2013 | GluMetrics | Debt Financing | 5.6M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 4/2019 | Vividion Therapeutics | Series B | 82M |
| 1/2007 | AcuFocus | Series D | 0 |
| 11/2002 | Vantage Oncology | Series A | 9M |
| 12/2008 | CELLutions Biosystems | Series B | 8.8M |
| 6/2017 | Monteris Medical | Series C | 26.6M |
| 12/2007 | RedBrick Health | Series B | 15M |
| 12/2015 | Inception IBD | Series A | 14.1M |
| 8/2000 | Syrrx | Series A | 5.1M |
| 3/2016 | Aprea | Series B | 50.6M |
| 8/2020 | Matterhorn Biosciences | Venture Round | 30M |
| 12/2013 | Inception Sciences | Series A | 10M |
| 5/2001 | CardioNow | Series C | 6M |
| 11/2009 | Standard BioTools | Venture Round | 0 |
| 4/2014 | Nuvaira | Series D | 42M |
| 9/2002 | Glaukos | Series A | 10M |
| 12/2016 | BlueRock Therapeutics | Series A | 225M |
| 5/2008 | Novasys Medical, Inc. | Series D | 49.5M |
| 9/2005 | Kythera Biopharmaceuticals | Seed Round | 1M |
| 4/2008 | Anaphore | Venture Round | 8M |
| 1/2009 | Anaphore | Series A | 25M |
| 4/2005 | NovaCardia | Series A | - |
| 6/2012 | Halscion, Inc. | Debt Financing | 4.3M |
| 10/2005 | Cameron Health | Series C | 15M |
| 12/2000 | Confirma | Series B | 12M |
| 9/2006 | NovaCardia | Series B | 48M |
| 6/2004 | Aria Biosystems | Series A | 5.5M |
| 5/2008 | Novasys Health | Venture Round | 49.5M |
| 7/2006 | Pathwork Diagnostics | Venture Round | 11M |
| 1/2008 | Benvenue Medical | Series B | 15M |
| 7/2007 | Ablation Frontiers | Series C | 0 |
| 11/2003 | Cameron Health | Series B | 29M |
| 9/2010 | Nuvaira | Series A | 3M |
| 9/2018 | CODA Biotherapeutics | Series A | 19M |
| 12/2018 | Black Diamond Therapeutics | Series A | 20M |
| 10/2012 | Cotera | Venture Round | 5M |
| 12/2016 | Veran Medical Technologies | Venture Round | 31M |
| 1/2004 | Standard BioTools | Series D | 21M |
| 12/2011 | Groove Biopharma | Series B | 6M |
| 3/2013 | Novira Therapeutics | Series A | 0 |
| 3/2008 | Ocular Therapeutix | Series B | 6M |
| 4/2009 | Ambrx | Series D | 10M |
| 10/2009 | Halscion, Inc. | Venture Round | 6M |
| 9/2003 | ParAllele Bioscience | Series B | 22.5M |
| 6/2009 | Anaphore | Series A | 13M |
| 9/2019 | Anokion | Series B | 40M |
| 3/2012 | OpGen | Series C | 0 |
| 8/2007 | MedManage Systems | Series E | 5M |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 1/2007 | Standard BioTools | Series E | 0 |
| 1/2011 | SpaceOAR | Debt Financing | 3M |
| 4/2014 | CRISPR Therapeutics | Series A | 25M |
| 4/2022 | Tempest Therapeutics | Post-IPO Equity | 0 |
| 4/2022 | Cimeio Therapeutics | Series A | 0 |
| 3/2007 | Amira Pharmaceuticals | Series B | 25M |
| 5/2010 | Sequent Medical | Series B | 15.6M |
| 11/2001 | Standard BioTools | Series C | 34M |
| 4/2023 | Abdera Therapeutics | Series A | - |
| 1/2023 | Belharra Therapeutics | Series A | 0 |
| 2/2011 | Ocular Therapeutix | Series D | 14M |
| 10/2020 | VectivBio | Equity | 110M |
| 12/2006 | NeoVista | Series C | 41M |
| 7/2008 | OraMetrix | Series C | 0 |
| 3/2012 | GluMetrics | Venture Round | 13.3M |
| 11/2011 | Hicuity Health | Series D | 0 |
| 7/2006 | Cameron Health | Series D | 31M |
| 3/2014 | Bird Rock Bio | Series B | 0 |
| 1/2009 | Bird Rock Bio | Series A | 25M |
| 10/2007 | Vital Therapies | Series C | 28.1M |
| 4/2004 | MedManage Systems | Series C | 6M |
| 10/2012 | Cerephex | Series A | 5.9M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 11/2008 | CodeRyte | Series D | 0 |
| 6/2007 | CELLutions Biosystems | Series B | 7M |
| 8/2012 | Intuity Medical | Venture Round | 12M |
| 8/2006 | Intuity Medical | Series C | 20M |
| 6/2002 | Intuity Medical | Series A | 3M |
| 1/2017 | Jecure Therapeutics | Series A | 20M |
| 4/2004 | ROX Medical | Series A | 3.6M |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 4/2023 | Abdera Therapeutics | Series A | - |
| 1/2023 | Belharra Therapeutics | Series A | 0 |
| 12/2022 | Launchpad Therapeutics | Series A | 0 |
| 11/2022 | iECURE | Series A | 0 |
| 11/2022 | Jnana Therapeutics | Series C | 0 |
| 8/2022 | Vector BioPharma | Series A | 0 |
| 4/2022 | Tempest Therapeutics | Post-IPO Equity | 0 |
| 4/2022 | Cimeio Therapeutics | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
